SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Noveris Health Sciences Inc. (MYCOF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 24/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MYCOF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.05
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-191.20 |
$84K |
$-4.64M |
-5524% |
| 2016 |
$-243.37 |
$0.00 |
$-7.6M |
- |
| 2017 |
$-311.15 |
$0.00 |
$-17.56M |
- |
| 2018 |
$-122.07 |
$207.66K |
$-13.36M |
-6431.4% |
| 2019 |
$-8.37 |
$125.57K |
$-3.73M |
-2968.2% |
| 2020 |
$-12.12 |
$58.49K |
$-27.56M |
-47114.2% |
| 2021 |
$-6.13 |
$7.49K |
$-28.72M |
-383287.9% |
| 2022 |
$-1.37 |
$0.00 |
$-11.85M |
- |
| 2023 |
$-0.68 |
$0.00 |
$-20.95M |
- |
| 2024 |
$-0.05 |
$0.00 |
$-3.15M |
- |
